Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70190 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Benjamin Douglas Liu and 3 co-authors. Institution: Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Body Mass Index, Obesity, Gastrointestinal Diseases. Cited 3 times so far (Crossref); 5 references.
Topics: Patientensicherheit
Abstract (original language)
We performed a re‐analysis of the gastrointestinal risks of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) in obese US adult patients without diabetes using the TriNetX database (GLP‐1 RA n = 8792; Bupropion‐naltrexone n = 8792) after accounting for initial BMI. GLP‐1 RA users had higher risks of gastroparesis (aHR 2.30; 95% CI 1.19–4.46) and biliary disease (aHR 1.27; 95% CI 0.96–1.39) but did not have a conclusively elevated risk of acute pancreatitis or obstruction. Not matching for BMI suggested an elevated pancreatitis risk (aHR 1.75; 95% CI 1.13–2.70). Semaglutide conferred superior weight loss but increased biliary risk.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
- Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
ORCID profiles: Benjamin Douglas Liu
Cite
APA
Liu, B. D., Veccia, D., Sun, Y., & Song, G. (2025). Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70190
Vancouver
Liu BD, Veccia D, Sun Y, Song G. Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70190
BibTeX
@article{Liu2025,
author = {Liu, Benjamin Douglas and Veccia, Donovan and Sun, Yan and Song, Gengqing},
title = {Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70190}
}
EUVIMED